PMC:7417114 / 45379-45909 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T236","span":{"begin":152,"end":158},"obj":"Body_part"},{"id":"T237","span":{"begin":394,"end":400},"obj":"Body_part"}],"attributes":[{"id":"A236","pred":"fma_id","subj":"T236","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A237","pred":"fma_id","subj":"T237","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Fedratinib (Inrebic)\n(Celgene) Not affected by high fat breakfast; 400mg oral dose: Cmax= 1804ng/mL, AUC= 26,870 ng/*h/mL\n(210);\nrapidly absorbed, peak plasma concentration after 3 h after dosing; exposure increased in a greater than dose-proportional manner;\nVd= 1770L Metabolized by CYP3A4, CYP2C19, flavin-containing monooxygenase 3;\nCYP3A4 inhibitor can increase exposure of tofacitinib in plasma 400 mg orally once daily; reduced dose for patients taking strong CYP3A inhibitors or with severe renal impairment;\n\u003e 92% binding"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T535","span":{"begin":52,"end":55},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T536","span":{"begin":152,"end":158},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T537","span":{"begin":219,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T538","span":{"begin":394,"end":400},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"Fedratinib (Inrebic)\n(Celgene) Not affected by high fat breakfast; 400mg oral dose: Cmax= 1804ng/mL, AUC= 26,870 ng/*h/mL\n(210);\nrapidly absorbed, peak plasma concentration after 3 h after dosing; exposure increased in a greater than dose-proportional manner;\nVd= 1770L Metabolized by CYP3A4, CYP2C19, flavin-containing monooxygenase 3;\nCYP3A4 inhibitor can increase exposure of tofacitinib in plasma 400 mg orally once daily; reduced dose for patients taking strong CYP3A inhibitors or with severe renal impairment;\n\u003e 92% binding"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T400","span":{"begin":302,"end":308},"obj":"Chemical"},{"id":"T401","span":{"begin":337,"end":353},"obj":"Chemical"},{"id":"T402","span":{"begin":344,"end":353},"obj":"Chemical"},{"id":"T403","span":{"begin":379,"end":390},"obj":"Chemical"},{"id":"T404","span":{"begin":473,"end":483},"obj":"Chemical"}],"attributes":[{"id":"A400","pred":"chebi_id","subj":"T400","obj":"http://purl.obolibrary.org/obo/CHEBI_30527"},{"id":"A401","pred":"chebi_id","subj":"T401","obj":"http://purl.obolibrary.org/obo/CHEBI_86501"},{"id":"A402","pred":"chebi_id","subj":"T402","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A403","pred":"chebi_id","subj":"T403","obj":"http://purl.obolibrary.org/obo/CHEBI_71200"},{"id":"A404","pred":"chebi_id","subj":"T404","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Fedratinib (Inrebic)\n(Celgene) Not affected by high fat breakfast; 400mg oral dose: Cmax= 1804ng/mL, AUC= 26,870 ng/*h/mL\n(210);\nrapidly absorbed, peak plasma concentration after 3 h after dosing; exposure increased in a greater than dose-proportional manner;\nVd= 1770L Metabolized by CYP3A4, CYP2C19, flavin-containing monooxygenase 3;\nCYP3A4 inhibitor can increase exposure of tofacitinib in plasma 400 mg orally once daily; reduced dose for patients taking strong CYP3A inhibitors or with severe renal impairment;\n\u003e 92% binding"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1484","span":{"begin":285,"end":291},"obj":"Gene"},{"id":"1485","span":{"begin":293,"end":300},"obj":"Gene"},{"id":"1486","span":{"begin":302,"end":335},"obj":"Gene"},{"id":"1487","span":{"begin":337,"end":343},"obj":"Gene"},{"id":"1488","span":{"begin":467,"end":472},"obj":"Gene"},{"id":"1556","span":{"begin":444,"end":452},"obj":"Species"}],"attributes":[{"id":"A1484","pred":"tao:has_database_id","subj":"1484","obj":"Gene:1576"},{"id":"A1485","pred":"tao:has_database_id","subj":"1485","obj":"Gene:1557"},{"id":"A1486","pred":"tao:has_database_id","subj":"1486","obj":"Gene:2328"},{"id":"A1487","pred":"tao:has_database_id","subj":"1487","obj":"Gene:1576"},{"id":"A1488","pred":"tao:has_database_id","subj":"1488","obj":"Gene:1576"},{"id":"A1556","pred":"tao:has_database_id","subj":"1556","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Fedratinib (Inrebic)\n(Celgene) Not affected by high fat breakfast; 400mg oral dose: Cmax= 1804ng/mL, AUC= 26,870 ng/*h/mL\n(210);\nrapidly absorbed, peak plasma concentration after 3 h after dosing; exposure increased in a greater than dose-proportional manner;\nVd= 1770L Metabolized by CYP3A4, CYP2C19, flavin-containing monooxygenase 3;\nCYP3A4 inhibitor can increase exposure of tofacitinib in plasma 400 mg orally once daily; reduced dose for patients taking strong CYP3A inhibitors or with severe renal impairment;\n\u003e 92% binding"}

{"project":"LitCovid-sentences","denotations":[{"id":"T359","span":{"begin":0,"end":20},"obj":"Sentence"},{"id":"T360","span":{"begin":21,"end":83},"obj":"Sentence"},{"id":"T361","span":{"begin":84,"end":121},"obj":"Sentence"},{"id":"T362","span":{"begin":122,"end":128},"obj":"Sentence"},{"id":"T363","span":{"begin":129,"end":259},"obj":"Sentence"},{"id":"T364","span":{"begin":260,"end":336},"obj":"Sentence"},{"id":"T365","span":{"begin":337,"end":516},"obj":"Sentence"},{"id":"T366","span":{"begin":517,"end":530},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fedratinib (Inrebic)\n(Celgene) Not affected by high fat breakfast; 400mg oral dose: Cmax= 1804ng/mL, AUC= 26,870 ng/*h/mL\n(210);\nrapidly absorbed, peak plasma concentration after 3 h after dosing; exposure increased in a greater than dose-proportional manner;\nVd= 1770L Metabolized by CYP3A4, CYP2C19, flavin-containing monooxygenase 3;\nCYP3A4 inhibitor can increase exposure of tofacitinib in plasma 400 mg orally once daily; reduced dose for patients taking strong CYP3A inhibitors or with severe renal impairment;\n\u003e 92% binding"}

{"project":"2_test","denotations":[{"id":"32778962-27136912-84130718","span":{"begin":123,"end":126},"obj":"27136912"}],"text":"Fedratinib (Inrebic)\n(Celgene) Not affected by high fat breakfast; 400mg oral dose: Cmax= 1804ng/mL, AUC= 26,870 ng/*h/mL\n(210);\nrapidly absorbed, peak plasma concentration after 3 h after dosing; exposure increased in a greater than dose-proportional manner;\nVd= 1770L Metabolized by CYP3A4, CYP2C19, flavin-containing monooxygenase 3;\nCYP3A4 inhibitor can increase exposure of tofacitinib in plasma 400 mg orally once daily; reduced dose for patients taking strong CYP3A inhibitors or with severe renal impairment;\n\u003e 92% binding"}